Key clinical point: Patients with newly diagnosed multiple myeloma had similar outcomes whether they received carfilzomib once or twice a week.
Major finding: There was no significant between-group difference in median progression-free survival (P= .26) or 3-year overall survival (P = .5).
Study details: A pooled analysis of data on 121 patients taken from a phase 1/2 trial and a phase 2 trial.
Disclosures: Both trials were sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland in collaboration with Fondazione Neoplasie Sangue ONLUS and supported by funding from Amgen (Onyx Pharmaceuticals). Dr. Bringhen reported relationships with Amgen and other companies. Coauthor Antonio Palumbo, MD, is an employee of Takeda, and other authors reported relationships with a range of companies.
Bringhen S et al. Haematologica. 2019 Feb 7. doi: 10.3324/haematol.2018.208272.